Currently Enrolling Trials
Maxalt (rizatriptan benzoate) is a serotonin (5-HT) 1B/1D receptor agonist (triptan).
Maxalt is specifically indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age.
Maxalt is supplied as tablets and orally disintegrating tablets. The recommended dose is
- Adults: 5 or 10 mg single dose; separate repeat doses by at least two hours; maximum dose in a 24-hour period: 30 mg
- Pediatric patients 6 to 17 years: 5 mg single dose in patients less than 40 kg (88 lb); 10 mg single dose in patients 40 kg (88 lb) or more
Mechanism of Action
Rizatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Maxalt presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
Adverse effects associated with the use of Maxalt may include, but are not limited to, the following:
- pain/pressure sensation
Clinical Trial Results
In clinical studies it was found that approximately 70% of patients who took Maxalt 10mg reported pain relief at two hours, while 60% of patients who took the 5mg dose reported pain relief at two hours as well. Both formulations will be made available in 10mg and 5mg strengths.